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ARTICLE
Clinical Study
Safety and pharmacokinetics of MM-302, a HER2-targeted
antibody–liposomal doxorubicin conjugate, in patients with
advanced HER2-positive breast cancer: a phase 1
dose-escalation study
Pamela Munster1, Ian E. Krop2, Patricia LoRusso3, Cynthia Ma4, Barry A. Siegel5, Anthony F. Shields6, István Molnár7,
Thomas J. Wickham7, Joseph Reynolds7, Karen Campbell7, Bart S. Hendriks7, Bambang S. Adiwijaya7, Elena Geretti7,
Victor Moyo7 and Kathy D. Miller8
BACKGROUND: This phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody–liposomal
doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer.
METHODS: Patients were enrolled in four cohorts: MM-302 monotherapy (8, 16, 30, 40, and 50mg/m2 every 4 weeks [q4w]);
MM-302 (30 or 40 mg/m2 q4w) plus trastuzumab (4 mg/kg q2w); MM-302 (30 mg/m2) plus trastuzumab (6 mg/kg) q3w; MM-302 (30
mg/m2) plus trastuzumab (6 mg/kg) and cyclophosphamide (450 mg/m2) q3w.
RESULTS: Sixty-nine patients were treated. The most common adverse events (AEs) were fatigue and nausea. Grade 3/4 AEs of
special interest included neutropenia, fatigue, mucosal inﬂammation, anemia, thrombocytopenia, febrile neutropenia, and palmar-
plantar erythrodysesthesia. The MTD was not reached. With MM-302 ≥ 30mg/m2, overall response rate (ORR) was 13% and median
progression-free survival (mPFS) 7.4 months (95% CI: 3·5–10·9) in all arms. In 25 anthracycline-naïve patients, ORR was 28·0% and
mPFS 10·9 months (95% CI: 1·8–15·3). Imaging with 64Cu-labeled MM-302 visualized tumor-drug penetrance in tumors throughout
the body, including the brain.
CONCLUSION: MM-302 monotherapy, in combination with trastuzumab, or trastuzumab plus cyclophosphamide, was well
tolerated and showed promising efﬁcacy. The selected phase 2 MM-302 dose was 30 mg/m2 plus 6 mg/kg trastuzumab q3w.
British Journal of Cancer (2018) 119:1086–1093; https://doi.org/10.1038/s41416-018-0235-2
BACKGROUND
Human epidermal growth factor receptor 2 (HER2)-targeted
anticancer therapies such as trastuzumab, pertuzumab, and
adotrastuzumab emtansine (T-DM1) have transformed the treat-
ment of HER2-positive advanced/metastatic breast cancer.1–3
Despite these improvements, the disease ultimately progresses,
and new treatment strategies are required.
Anthracyclines, such as doxorubicin, are efﬁcacious in the
treatment of HER2-positive breast cancer.4–6 However, their use in
early-stage trastuzumab-containing breast cancer regimens is
limited by their adverse effects on the heart,2 and some studies
show that a taxane-based regimen may have similar efﬁcacy in the
adjuvant and neoadjuvant settings.6,7 There is a strong need for
efﬁcacious regimens after taxane failure in the metastatic setting,
and less toxic early-stage regimens. Compared with free
doxorubicin, liposomal formulations of doxorubicin have less
cardiac toxicity and fewer side effects.8–16 The introduction of
targeted antibody conjugates has provided great promise to
maximize cancer cell uptake while minimizing systemic toxicity.
Targeted delivery of doxorubicin to HER2-overexpressing cells
would allow use of one of the most effective chemotherapeutic
agents while sparing the heart.
MM-302 is a HER2-targeted PEGylated antibody–liposomal
doxorubicin conjugate that targets HER2overexpressing tumor
cells, delivers doxorubicin to tumor cells, and limits exposure to
healthy cells such as cardiomyocytes (Supplemental Fig. 1).17,18 In
preclinical models of HER2-positive breast cancer, MM-302
demonstrated superior antitumor activity compared to both
doxorubicin and PEGylated liposomal doxorubicin.18 MM302 and
trastuzumab bind different epitopes of HER2, and the combination
of MM-302 and trastuzumab demonstrated enhanced antitumor
activity compared with either agent alone in HER2overexpressing
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tumor xenograft models.12,19–21 Preclinical studies have also
shown that cyclophosphamide pretreatment increased the
delivery and antitumor activity of MM-302.22 These ﬁndings
support clinical investigation of MM-302 in combination with
trastuzumab and trastuzumab plus cyclophosphamide. Here we
report the results from the ﬁrst-in-human phase 1 study of MM-
302 in patients with advanced HER2-positive breast cancer.
METHODS
Study design
This phase 1, open-label, multicenter, dose-escalation study
evaluated the safety, tolerability, and pharmacokinetics (PK) of
MM-302 as a monotherapy (arm 1), in combination with
trastuzumab (arm 2 and arm 3), or trastuzumab plus cyclopho-
sphamide (arm 4) in patients with advanced HER2-positive breast
cancer (ClinicalTrials.gov Identiﬁer: NCT01304797).
The primary objectives were to assess safety and tolerability,
and to determine the maximum tolerated dose (MTD) and phase 2
dose of MM-302 as a monotherapy, in combination with
trastuzumab or trastuzumab plus cyclophosphamide. Secondary
objectives were to describe dose-limiting toxicities (DLTs),
objective response rate (ORR; conﬁrmed complete response [CR]
or partial response [PR]), clinical beneﬁt rate (CBR; conﬁrmed CR,
PR or stable disease at 24 weeks), duration of response,
progression-free survival (PFS), immunogenicity and PK of MM-
302 in patients enrolled in arm 1–4. Exploratory objectives
investigated the correlation of clinical activity with levels of
HER2 ampliﬁcation or protein expression, and MM-302 biodis-
tribution and tumor deposition.
The trial was conducted at ﬁve sites in the United States and
was approved by the Institutional Review Board at each site. All
patients provided written informed consent prior to study
enrollment in accordance with the Declaration of Helsinki, the
Code of Federal Regulations and local regulatory requirements.
Patients
Key inclusion criteria were: histologically or cytologically con-
ﬁrmed HER2-positive locally advanced/metastatic breast cancer;
tumor amenable to biopsy; measurable disease per Response
Evaluation Criteria in Solid Tumors (RECIST) version 1·1; age ≥ 18
years; Eastern Cooperative Oncology Group (ECOG) performance
status 0 or 1; left ventricular ejection fraction (LVEF) ≥ 50%;
adequate renal/hepatic function and bone marrow reserves.
Patients with stable, treated central nervous system metastases
were allowed.
Key exclusion criteria were: previous cumulative anthracycline
total dose of > 300mg/m2 doxorubicin equivalent; signiﬁcant
cardiovascular problems.
Treatment
MM-302 (Merrimack Pharmaceuticals, Cambridge, MA, USA) was
administered by intravenous infusion over 60min and the dose
based on a doxorubicin hydrochloride equivalent basis. Patients
were sequentially enrolled in one of four arms (Table 1). A
standard ‘3+ 3’ dose escalation design was used starting with
MM-302 monotherapy (arm 1; 8, 16, 30, 40, and 50mg/m2)
administered once every 4 weeks (q4w) with expansion cohorts at
40 and 50mg/m2 (each containing 12 patients, respectively).
Arm 2 was a combination dose escalation of intravenous MM-302
Table 1. Treatment administration and dose-limiting toxicity






Arm 1: MM-302 monotherapy
Cohort MM-302 dose,
mg/m2, q4w
1 8 3 3·2 (1·3– 3·7) 0
2 16 4 1·3 (0·5–2·4) 0
3 30 3 1·9 (1·6–11·1) 0
4 40 12 8·0 (1·0–48·5) 0
5 50 12 2·6 (1·4–8·9) 0





1 30 4 6 4·2 (1·8–19·3) 1 Febrile neutropenia
2 40 4 4 7·2 (1·9–12·7) 0





1 30 6d 3 2·1 (1·4–8·1) 0
2 30 6 9 1·7 (0·5–8·3) 0







1 30 6 600 13 3·0 (0·7–28·8) 0
aThe ﬁrst dose was a 6mg/kg loading dose
bThe ﬁrst dose was an 8mg/kg loading dose
cFor the ﬁrst cycle, ~3–5mg/m2 64Cu-MM-302 was administered for the ﬁrst cycle only in addition to the MM-302 dose
dIn arm 3, cohort 1, trastuzumab was administered from cycle 2 onwards
eCyclophosphamide continued beyond cycle 4 at physician discretion and depending on tolerability
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(30 and 40mg/m2 q4w) plus intravenous trastuzumab (4 mg/kg
with 6 mg/kg loading) every 2 weeks (q2w). Arm 3 cohort 1
investigated MM-302 (30 mg/m2) on day 1 cycle 1, initially in three
patients; in subsequent cycles patients received trastuzumab (6*
or 8 mg/kg [*with 8 mg/kg loading] every 3 weeks [q3w]) on day 1
followed by MM-302 on day 6. After safety had been established
in the ﬁrst cohort, a larger expansion cohort (cohort 2) of nine
patients investigated trastuzumab administered on cycle 1 day 1,
followed by MM-302 and 64Cu-MM-302 on cycle 1 day 6. During
subsequent cycles, trastuzumab was administered q3w on day 1
Table 2. Patient baseline demographics
Arm 1 Arm 2 Arm 3 Arm 4 Total (safety
population)
Female gender, n (%) 34 (100) 10 (100) 12 (100) 13 (100) 69 (100)
Median (range) age 55·0 (31–75) 53·5 (45–68) 48·5 (37–65) 58·0 (43–71) 55·0 (31–75)
Ethnicity, n (%)
Caucasian 32 (94) 9 (90) 10 (83) 13 (100) 64 (93)
Black 2 (6) 0 2 (17) 0 4 (6)
Asian 0 1 (10) 0 0 1 (1)
ECOG performance status, n (%)
0 16 (47) 5 (50) 7 (58) 5 (39) 33 (48)
1 18 (53) 5 (50) 5 (42) 6 (62) 36 (52)
Median (range) time from ﬁrst diagnosis, months 72·8 (7·3–311·0) 89·7 (8·1–144·5) 46·3 (10·8–199·6) 85·4 (11·0–198·6) 69·1 (7·3–311·0)
Median (range) time from ﬁrst diagnosis of
metastatic disease, months
33·6 (0·1–199·5) 47·8 (5·0–101·1) 29·0 (7·6–76·1) 54·45 (1·2–198·0) 39·5 (0·1–199·5)
Disease status, n (%)
Locally advanced 0 0 0 2 (15) 2 (3)
Distant metastases 34 (100) 10 (100) 12 (100) 11 (85) 67 (97)
Disease stage at diagnosis, n (%)
IA 5 (15) 1 (10) 0 3 (23) 9 (13)
IB 1 (3) 0 0 0 1 (1)
IIA 6 (18) 2 (20) 1 (8) 2 (15) 11 (16)
IIB 5 (15) 2 (20) 1 (8) 1 (8) 9 (13)
IIIA 4 (12) 2 (20) 1 (8) 0 7 (10)
IIIB 0 0 0 1 (8) 1 (1)
IIIC 0 0 1 (8) 0 1 (1)
IV 4 (12) 1 (10) 6 (50) 3 (23) 14 (20)
Unknown 9 (27) 2 (20) 2 (17) 3 (23) 16 (23)
ER receptor status, n (%)
Positive 6 (18) 4 (40) 1 (8) 2 (15) 13 (19)
Negative 1 (3) 2 (20) 6 (50) 3 (23) 12 (17)
Unknown 27 (79) 4 (40) 5 (42) 8 (62) 44 (64)
PR receptor status, n (%)
Positive 3 (9) 2 (20) 2 (16) 1 (8) 8 (11)
Negative 4 (12) 4 (40) 5 (42) 4 (31) 17 (25)
Unknown 27 (79) 4 (40) 5 (42) 8 (61) 44 (64)
Median (range) number of prior anticancer therapies 5 (1–10) 4 (1–12) 4·5 (2–10) 5 (2–10) 5 (1–12)
Previous exposure to therapy, n (%)
Trastuzumab 34 (100) 9 (90) 12 (100) 13 (100) 68 (99)
Taxane 33 (97) 9 (90) 11 (92) 11 (85) 64 (93)
Lapatinib 23 (68) 6 (60) 6 (50) 7 (54) 42 (61)
Anthracycline 18 (53) 6 (60) 5 (42) 8 (62) 37 (54)
Ado-trastuzumab emtansine 10 (29) 4 (40) 11 (92) 10 (77) 35 (51)
(T-DM1)
Hormonal therapy 18 (53) 4 (40) 3 (25) 8 (62) 33 (48)
Pertuzumab 1 (3) 5 (50) 8 (67) 3 (23) 17 (25)
Prior surgery, n (%) 33 (97) 9 (90) 11 (92) 12 (92) 65 (94)
Prior radiotherapy, n (%) 23 (68) 7 (70) 9 (75) 8 (62) 47 (68)
CISH chromogenic in situ hybridization, ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, FISH ﬂuorescence in situ hybridization, HER2 human
epidermal growth factor receptor 2, IHC immunohistochemistry, PR progesterone receptor
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and a full therapeutic dose of non-radioactive MM-302 (30 mg/m2)
was administered q3w on day 6. Similarly, arm 4 investigated
intravenous cyclophosphamide (450 mg/m2 q3w) and trastuzu-
mab (6 mg/kg after 8 mg/kg loading) on day 1 followed by MM-
302 (30 mg/m2 q3w) on day 6 in 13 patients. Cyclophosphamide
administration in arm 4 continued beyond cycle 4 at physician
discretion and depending on tolerability.
Following treatment with unlabeled MM-302, patients in arms 3
and 4 also received 337–432 MBq 64Cu-MM-302 (64Cu-MM-302),
mass dosage 3–5mg/m2, during cycle 1, on the ﬁrst day of MM-
302 administration only, and then 2–3 positron emission
tomography/computed tomography (PET/CT) scans were
obtained immediately after administration and up to 2 days later
to assess 64Cu-MM-302 biodistribution and tumor deposition.23,24
Patients were treated until disease progression, unacceptable
toxicity, or withdrawal of consent. A 25% dose reduction was
permitted for any toxicity ≥ grade 3 that was considered related
and/or signiﬁcant by the investigator. Treatment could be paused
for ≤56 days to allow recovery from an adverse event (AE);
otherwise treatment was discontinued.
Patients experiencing an asymptomatic reduction in LVEF to
<50% or >10% absolute drop from baseline could continue
treatment at the discretion of the medical monitor, provided that
cardiac function tests were performed prior to each MM-302 dose.
Study treatment was discontinued permanently if LVEF did not
improve or declined further.
From September 2012, all patients starting treatment received
prophylactic premedication with 25–50mg diphenhydramine or
equivalent (administered orally ≤30min prior to MM-302 dosing
or intravenously immediately prior to MM-302 dosing) in cycle 1.
Patients who tolerated the initial dose without an infusion
reaction could discontinue premedication in subsequent cycles
according to investigator judgment.
Assessments
DLTs were evaluated during cycle 1 of treatment and AEs were
monitored throughout treatment and for 30 days after
administration of the last study drug dose, according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE) version 4·0.
Cardiac function was regularly monitored throughout the study.
Electrocardiograms were obtained at screening, prior to each
cycle, at study end, and at 30-day follow-up. Radionuclide
ventriculography or echocardiography was obtained at screening,
every 4 weeks for the ﬁrst three cycles then every 8 weeks
thereafter, at study end, and at 30-day follow-up.
Blood samples for PK analysis were collected immediately
before and after MM-302 infusion, and at approximately 2, 4, 8, 24,
48, and 72 h after the start of infusion, 8 days after treatment, at
study termination, and at 30-day follow-up. Samples were
analysed for total and encapsulated doxorubicin, as well as the
anti-HER2 single chain variable fragment (scFv), F5. Analysis was
performed comparing PK parameters to drug activity. Anti-drug
antibody samples were collected before dosing and at the onset
of any infusion reaction, at the resolution of the event, and at
28 days after the event.
ORR was assessed by RECIST version 1·1 at screening and every
8 weeks from ﬁrst dose. CBR, median duration of response, and
median PFS were calculated per dose cohort and for the overall
population.
Tumor biopsy samples were collected 72 h after MM-302 dosing
to measure HER2, microvessel density, and microscopic distribu-
tion of MM-302 within the tumor. A subgroup of patients received
64Cu-MM-302 to map biodistribution and tumor deposition, under
a companion imaging protocol described elsewhere.23,24
Statistical analysis
Patients who received at least a partial infusion of MM-302
during this period were included in the safety and efﬁcacy
population. Efﬁcacy was also reported separately for patients
who received ≥30 mg/m2 MM-302. Safety, efﬁcacy, and PK
parameters were summarized using descriptive statistics for
continuous variables and frequency distributions for categorical
variables.
Table 3. Most common treatment-emergent adverse events all grade occurring in >20% of patients in the overall population and grade 3/4 adverse
events occurring in more than two patients in any treatment arm (safety population)
Arm 1(n= 34) Arm 2 (n= 10) Arm 3 (n= 12) Arm 4 (n= 13) Total (n= 69)
All AEs G3/4 All AEs G3/4 All AEs G3/4 All AEs G3/4 All AEs G3/4
Fatigue 21 (62) 0 4 (40) 0 6 (50) 1 (11) 3 (23) 1 (8) 34 (49) 2 (3)
Nausea 19 (56) 0 2 (20) 0 7 (58) 0 6 (46) 0 34 (49) 0
Decreased appetite 13 (38) 0 2 (20) 0 3 (25) 0 2 (15) 0 20 (29) 0
Vomiting 9 (27) 0 1 (10) 0 4 (33) 0 5 (39) 0 19 (28) 0
Cough 8 (24) 0 2 (20) 0 5 (42) 0 3 (23) 0 18 (26) 0
Diarrhea 7 (21) 0 3 (30) 0 3 (25) 0 4 (31) 0 17 (25) 0
Constipation 7 (21) 0 2 (20) 0 3 (25) 0 4 (31) 0 16 (23) 0
Stomatitis 8 (24) 0 4 (40) 0 2 (17) 0 2 (15) 0 16 (23) 0
Dyspnea 5 (15) 2 (6) 2 (20) 0 5 (42) 0 4 (31) 0 16 (23) 0
Neutropenia 9 (27) 6 (18) 0 0 3 (25) 0 3 (23) 1 (8) 15 (22) 7 (10)
Rash 9 (27) 0 1 (10) 0 1 (8) 0 3 (23) 0 14 (20) 0
Infusion-related reaction 5 (15) 0 2 (20) 0 5 (42) 0 2 (15) 0 14 (20) 0
Mucosal inﬂammation 5 (15) 2 (6) 1 (10) 0 4 (33) 0 3 (23) 0 13 (19) 2 (3)
Leukopenia 5 (15) 2 (6) 0 0 0 0 1 (8) 0 6 (9) 2 (3)
The additional following grade 3/4 adverse events were each seen in one patient only in the separate treatment arms: anemia, lymphopenia,
thrombocytopenia, alanine aminotransferase increased, aspartate aminotransferase increased, bilirubin conjugated increased, hematocrit increased,
depression, palmar-plantar erythrodysesthesia syndrome, (arm 1); febrile neutropenia, neutropenic infection, lymphoedema, (arm 2); inﬂuenza, presyncope,
hip fracture, blood alkaline phosphatase increased, blood bilirubin increased, hyponatremia, cognitive disorder, mental status changes, breast pain, pulmonary
embolism, (arm 3); lymphopenia, white blood cell count decreased, hypoalbuminemia, hyponatremia (arm 4)
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RESULTS
Seventy-three patients were enrolled between 25 July 2011 and
24 June 2014, 69 of whom received study treatment in four arms
with MM-302 either alone or in combination with trastuzumab
and cyclophosphamide (Table 1 and Supplemental Fig. 2). Patient
demographics and characteristics are described in Table 2. At data
cutoff (18 August 2016), study treatment was ongoing for one
patient receiving MM-302 monotherapy and one patient receiving
MM-302 plus trastuzumab and cyclophosphamide (Supplemental
Fig. 2).
Patients remained on study treatment for a median of
3·0 months (range: 0·5–48·5). Of note, as of data cutoff, one
patient had received >49 cycles of 40 mg/m2 MM-302 q4w for a
cumulative dose of 1960mg/m2 MM-302 and was continuing to
receive study treatment.
The most common AEs of any grade were fatigue and nausea
(MM-302 monotherapy plus trastuzumab), or nausea and vomiting
(MM-302 plus trastuzumab and cyclophosphamide) (Table 3).
Speciﬁc AEs for doxorubicin, e.g., cardiac toxicity, were followed as
AEs of special interest (Supplemental Table 1). Grade 3 or 4
treatment-emergent AEs occurred in 24/69 patients (Table 3);
neutropenia was the most common in 6/34 (18%) patients
receiving monotherapy and 1/13 (8%) patients receiving MM-
302 plus trastuzumab. Median time to absolute neutrophil count
nadir was 23 days. The highest incidence of grade 3/4 AEs was
seen with 50 mg/m2 MM-302 monotherapy (n= 5/12; 42%). As
this occurred beyond cycle 1, neutropenia did not meet the
criteria of DLT. Neutropenia was primarily observed in patients
receiving higher dose intensities (>10mg/m2/week). In addition,
grade 3/4 neutropenia was observed only in patients previously
treated with an anthracycline (Supplemental Figure 4).
Seventeen patients had ≥1 dose interruption, and of these, 15
patients had ≥1 dose interruption due to infusion reaction. Eight
patients discontinued treatment due to an AE (n= 1 for each of
convulsion; aphasia/face edema; peripheral sensory neuropathy;
cardiac failure [see below]; neutropenia; hypoxia; thrombocytope-
nia; back pain/dyspnea/infusion-related reaction). Three patients
experienced ≥1 treatment-related serious AE (anemia/neutrope-
nia/thrombocytopenia; palmar-plantar erythrodysesthesia syn-
drome; febrile neutropenia). Only one DLT (febrile neutropenia)
was observed in a patient treated with 30 mg/m2 MM-302 q4w
plus 4 mg/kg trastuzumab q2w (Table 1). There were no
treatment-related deaths. The MTD was not deﬁned in this trial;
however, post-cycle 1 neutropenia prompted the recommenda-
tion of a phase 2 dose of 30mg/m2 q3w or 40 mg/m2 q4w.
There were no reported cardiac AEs ≥grade 2 with MM-302
monotherapy, and cardiac AEs were infrequent in the MM-302
combination arms with no serious AEs. Six patients on the
combination arms had a protocol-deﬁned asymptomatic decline
in LVEF deﬁned as (1) a post-baseline measurement <50%, or 2) a
post-baseline measurement that was a reduction of > 10 absolute
percentage points from baseline (Fig. 1): three patients had LVEF
< 50%; four patients had reversible declines; one patient had a
decline to 47% noted at off-study assessment; one patient
(receiving 30mg/m2 MM-302 and 6mg/kg trastuzumab q3w)
was observed twice to have a range of 45–50% LVEF (unchanged
off-study). This patient discontinued treatment because of LVEF
decline. Eleven patients had lifetime cumulative anthracycline
exposure >550mg/m2 with no protocol-deﬁned LVEF changes
(Fig. 1).
Total doxorubicin, encapsulated doxorubicin, and anti-HER scFv
F5 plasma concentrations were measured (Supplemental Fig. 3)
and pharmacokinetic parameters summarized in Supplemental
Table 2. The terminal half-lives at the ﬁrst cycle are estimated
using non-compartmental analysis to be 47·3, 44·8, and 63·3 h for
total doxorubicin, encapsulated doxorubicin, and F5, and these
values increased by ~15% in subsequent cycles. Measurements of

































































































































































































































Fig. 1 Cardiac safety. Left ventricular ejection fraction (LVEF) is shown by patient (black horizontal line denotes baseline value, box denotes
range over treatment period). Treatment received, including dose of MM-302, is shown below graph for each patient as well as cumulative
doxorubicin exposure. Grey highlighting shows the 11 patients with cumulative anthracycline exposure >550mg/m2
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<7.5 no prior anthracycline
≥7.5 no prior anthracycline
<7.5 mg/m2/wk MM-302, no prior anthracycline
≥7.5 mg/m2/wk MM-302, no prior anthracycline
≥7.5 mg/m2/wk MM-302, with prior anthracycline












































































0 2 4 6 8 10 12 14 16 18 20 22 24
Time (months)
26 28 30 32 34 36 38 40 42 44 46 48
Anthracycline naïve (n = 25)











* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *















































Fig. 2 a Maximum change from baseline in tumor size (sum of target lesions) and progression-free survival (PFS). b Maximum change from
baseline in tumor size (sum of target lesions) and PFS in patients treated with MM-302 ≥30mg/m2 (safety population). c Kaplan-Meier graph of













Fig. 3 a, b Are representative axial CT and PET images in two patients with HER2-positive metastatic breast cancer at 24-h post-administration
of 64Cu-MM-302, respectively, of the head. Brain lesion (as conﬁrmed by MRI at screening) is indicated by the blue contour and is shown to
have signiﬁcant uptake of 64Cu-MM-302 as seen in (b). c–f Show 64Cu-MM-302 deposition in a skin lesion in another patient. c–f Are
representative axial and sagittal views, respectively, of the skin lesion (as indicated by the cyan cross hair marker). g Immunoﬂuorescence
images (20x) of a day 3 liver biopsy of a study patient (IHC 3+ and FISH positive on FFPE) treated with 30 mg/m2 MM-302 q4w. The biopsy was
stained for cytokeratin (CK, yellow) to identify tumor cells, HER2 (red), PEG (green) to identify MM-302, and nuclei with Hoechst (blue) (left four
panels). Merged images (right panel) show clusters of HER2-positive tumor cells with internalized liposomes (arrows). CT computed
tomography, HER2 human epidermal growth factor receptor 2, MRI magnetic resonance imaging, PET positron emission tomography, FFPE
formalin-ﬁxed parafﬁn-embedded, FISH ﬂuorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, IHC
immunohistochemistry, PEG polyethylene glycol, q4w every 4 weeks
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analytes are highly correlated; 98% doxorubicin remained
encapsulated in samples collected up to 1 week. Area under the
curve (AUC) and maximum concentration (Cmax) of total and
encapsulated doxorubicin and F5 increased proportionally with
dose.
In four patients, positively conﬁrmed anti-drug antibodies
(ADAs) non-speciﬁc to MM-302 were detected at baseline, prior
to any MM-302 treatment, and were also detected post-baseline.
In two other patients, ADAs were detected post-baseline at cycle 2
and 6 and titer levels remained ≤ 40 relative luminescence units
(RLU); both had negative ADAs at study end.
The patient population in this trial was heavily pretreated, with
a median of ﬁve prior therapies and 99% of patients had received
prior trastuzumab. Overall, ORR was 12% (n= 8/69; 95% CI: 5·1,
21·6) and CBR was 28% (n= 19/69; 95% CI: 17·5, 39·6). No
responses were observed in patients receiving <30mg/m2 of MM-
302. Median PFS was 4·4 months (95% CI: 3·1, 8·6).
In patients receiving ≥30mg/m2 MM-302 (n= 62: 27 mono-
therapy; 22 plus trastuzumab; 13 plus trastuzumab/cyclopho-
sphamide), ORR was 13% (n= 8/62; two CR and six PR) (Fig. 2a),
CBR was 30·6% (n= 19/62) and median PFS was 7·4 months (95%
CI: 3·5–10·9) (Fig. 2b). Among patients receiving ≥30mg/m2 MM-
302, in the anthracycline-exposed group (n= 37), ORR was 3% (n
= 1/37), CBR was 24% (n= 9/37) and median PFS 5·6 months (95%
CI: 3·5–8·6). In the anthracycline-naïve subgroup (n= 25), ORR was
28% (n= 7/25), CBR was 40% (n= 10/25) and median PFS was
10·9 months (95% CI: 1·8−15·3) (Fig. 2a, b). A relationship was
observed between clinical efﬁcacy and dose, suggesting that a
greater reduction in tumor burden was observed at doses ≥30
mg/m2 (Fig. 2c and Supplementary Figure 5).
PET/CT following administration of 64Cu-MM-302 revealed diverse
locations of tumor MM-302 uptake in different patients, including
skin, breast, liver, and brain (Fig. 3a–f), and with different lesion
intensities both intra- and interpatient.23 High levels of MM-302 in
the blood and liver at the time points used for imaging were
consistent with the anticipated biodistribution for a PEGylated
liposomal agent. Furthermore, HER2-mediated delivery of MM-302
to HER2-overexpressing tumor cells was conﬁrmed in multiple
evaluable biopsies post-MM-302 treatment by co-localization of anti-
PEG, anti-HER2, and anti-cytokeratin antibodies (Fig. 3g).
DISCUSSION
In this phase 1, open-label, dose-escalation study, MM-302 was
well tolerated and active in patients with HER2-positive advanced/
metastatic breast cancer. The study population was heavily
pretreated with a median of ﬁve prior regimens for metastatic
disease. The main study objective was to determine the safety of
MM-302 as a monotherapy and in combination with trastuzumab
and cyclophosphamide. Consistent with the nature of a phase 1
dose escalation study, conclusions on efﬁcacy are confounded by
the heterogeneous doses and schedules of MM-302 used and the
multitude of monotherapy and combination therapy cohorts.
Nonetheless, there is notable lasting activity without cumulative
toxicity.
MM-302 was designed to target delivery of doxorubicin to
tumors via anti-HER2-directed antibodies. Owing to the low level
of HER2-expression on cardiomyocytes, preclinical studies with
MM-302 show no uptake into human stem cell-derived cardio-
myocytes and no effect on cell viability.18 However, to safeguard
against cardiac toxicity, effects on the heart were monitored very
closely. No cardiac AEs were observed in patients treated with
MM-302 monotherapy. With MM-302 in combination with
trastuzumab, with or without cyclophosphamide, cardiac AEs
were infrequent with no serious AEs.
MM-302 activity correlated with AUC and, in general, higher
activity was observed at doses ≥10mg/m2/week (30 mg/m2 q3w
and 40mg/m2 q4w) (Fig. 3 and Supplemental Figure 5). Although
MTD was not reached at 50 mg/m2 q4w (12·5 mg/m2/week), dose
intensity of 10 mg/m2/week was also active and had fewer
cumulative incidences of neutropenia. Based on phase 1 results,
the recommended phase 2 dose was 30 mg/m2 q3w MM-302 (10
mg/m2/week) in combination with trastuzumab 6mg/kg q3w
(with 8 mg/kg loading).
The observed activity of MM-302 is promising. Median PFS of
7·4 months with ≥30mg/m2 MM-302 monotherapy, in combina-
tion with trastuzumab or with trastuzumab and cyclophospha-
mide, compares favourably with recent late-stage HER2-positive
clinical trials that demonstrated median PFS of 3·3 months in
patients treated with the physician’s choice.25 Furthermore, in the
present study, the observed PFS and ORR in patients not
previously exposed to an anthracycline were 10·9 months and
28%, respectively. Multiple studies of liposomal doxorubicin have
observed similar trends, with improved activity in patients not
previously exposed to an anthracycline compared to those
previously exposed.12,20,21 Additionally, grade 3 palmar-plantar
erythrodysesthesia with MM-302 (n= 1/69; 1%) was less frequent
than that reported for the combination of liposomal doxorubicin
plus trastuzumab (n= 9/30; 30%; respectively).9
Exploratory analyses of tumor biopsies support a HER2-
targeting mechanism for MM-302 consistent with preclinical data.
Tumor deposition data using 64Cu-MM-302 PET/CT revealed the
potential of MM-302 to be delivered to difﬁcult metastatic
locations such as brain metastases.23
In summary, these data suggest that MM302 monotherapy, in
combination with trastuzumab or trastuzumab and cyclopho-
sphamide has a manageable safety proﬁle and promising clinical
activity in patients with advanced HER2-positive breast cancer.
MM-302 30mg/m2 in combination with 6 mg/kg trastuzumab
every 3 weeks was selected as the recommended phase 2 study
dose. This study is now completed, and further clinical studies are
under discussion.
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